No open-market selling at Kailera Therapeutics, Inc. in the past year, which is unusual. Instead five insiders bought about $326.8 million worth of KLRA.
Biggest single buyer: BCPE Perseus Investor, LP, 10% Owner, with roughly $134.4 million.
99 investment managers listed KLRA in their latest 13F filings (Q2 2026); more funds bought than sold. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | RTW INVESTMENTS, LP | 10% Owner | Buy | 500,000 | $16.00 | $8.0M | SEC |
| Apr 20, 2026 | BCPE Perseus Investor, LP | 10% Owner | Buy | 8,398,438 | $16.00 | $134.4M | SEC |
| Apr 20, 2026 | Koppel Adam | Director | Buy | 1,562,500 | $16.00 | $25.0M | SEC |
| Apr 20, 2026 | BCLS Fund IV Investments GP, LLC | 10% Owner | Buy | 1,562,500 | $16.00 | $25.0M | SEC |
| Apr 20, 2026 | Kaplan Andrew T. | Director | Buy | 8,398,438 | $16.00 | $134.4M | SEC |
In the last 12 months Kailera Therapeutics, Inc. insiders made open-market purchases worth about $326.8 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in KLRA was filed on 2026-04-22.
99 investment managers reported holding KLRA in SEC Form 13F filings for Q2 2026.
No congressional trades in KLRA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).